- Conditions
- Cystic Fibrosis
- Interventions
- Ivacaftor, Placebo
- Drug
- Lead sponsor
- Vertex Pharmaceuticals Incorporated
- Industry
- Eligibility
- 6 Years and older
- Enrollment
- 70 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2013
- U.S. locations
- 29
- States / cities
- Birmingham, Alabama • Palo Alto, California • Hartford, Connecticut + 26 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 25–48
of 24
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Hemangioma, Infant
- Interventions
- topical 0.5% Timolol, Control (placebo) group
- Drug
- Lead sponsor
- Oregon Health and Science University
- Other
- Eligibility
- 1 Month to 8 Months
- Enrollment
- 6 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2014
- U.S. locations
- 1
- States / cities
- Portland, Oregon
- Conditions
- Chronic Spontaneous Urticaria
- Interventions
- LOU064 25 mg (b.i.d), Placebo, LOU064 25 mg (b.i.d) as a tablet.
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 470 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2024
- U.S. locations
- 26
- States / cities
- Birmingham, Alabama • North Little Rock, Arkansas • Bakersfield, California + 23 more
- Conditions
- Obesity
- Interventions
- Zonisamide SR placebo/ bupropion SR placebo, Zonisamide SR placebo/ bupropion SR 360 mg/day, Zonisamide SR 120 mg/day/ bupropion SR placebo, Zonisamide SR 360 mg/day/ bupropion SR placebo, Zonisamide SR 120 mg/day/ bupropion SR 360 mg/day, Zonisamide SR 360 mg/day/ bupropion SR 360 mg/day
- Drug
- Lead sponsor
- Orexigen Therapeutics, Inc
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 729 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2009
- U.S. locations
- 20
- States / cities
- Fairhope, Alabama • La Jolla, California • Denver, Colorado + 17 more
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- vildagliptin, Glimepiride, LAF237 placebo
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 515 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2005
- U.S. locations
- 1
- States / cities
- East Hanover, New Jersey
- Conditions
- Multiple Sclerosis
- Interventions
- fampridine, Placebo
- Drug
- Lead sponsor
- Biogen
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 646 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2016
- U.S. locations
- 17
- States / cities
- Cullman, Alabama • Phoenix, Arizona • San Diego, California + 12 more
- Conditions
- Autism Spectrum Disorder
- Interventions
- IGF-1, Placebo/saline
- Drug
- Lead sponsor
- Icahn School of Medicine at Mount Sinai
- Other
- Eligibility
- 5 Years to 12 Years
- Enrollment
- 3 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2017
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Locally Advanced or Metastatic Non Small Cell Lung Cancer Stage IIIb - IV
- Interventions
- Selumetinib 75 mg, Docetaxel 75 mg/m2, Docetaxel 60 mg/m2, Placebo
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 130 Years
- Enrollment
- 212 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2022
- U.S. locations
- 13
- States / cities
- Santa Monica, California • Aurora, Colorado • Hollywood, Florida + 9 more
- Conditions
- Depression
- Interventions
- pregnenolone, placebo
- Dietary Supplement · Other
- Lead sponsor
- Beth Israel Deaconess Medical Center
- Other
- Eligibility
- 40 Years to 60 Years · Female only
- Enrollment
- 80 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2027
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Coma, Heart Arrest, Anoxia
- Interventions
- Amantadine, Placebo
- Drug
- Lead sponsor
- Jon Rittenberger, MD
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 14 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2018
- U.S. locations
- 4
- States / cities
- Portland, Maine • Boston, Massachusetts • Pittsburgh, Pennsylvania
- Conditions
- Staphylococcal Infection
- Interventions
- Cephalexin, Clindamycin, Placebo, Trimethoprim-sulfamethoxazole
- Drug · Other
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 13 Years and older
- Enrollment
- 2,265 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2013
- U.S. locations
- 5
- States / cities
- Phoenix, Arizona • Sylmar, California • Baltimore, Maryland + 2 more
- Conditions
- Traumatic Brain Injury
- Interventions
- Atorvastatin Calcium, Minocycline Hydrochloride, Candesartan Cilexetil, Placebo
- Drug
- Lead sponsor
- University of California, San Francisco
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 672 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2029
- U.S. locations
- 18
- States / cities
- San Francisco, California • Indianapolis, Indiana • Lexington, Kentucky + 14 more
- Conditions
- Dry Eye
- Interventions
- 0.25% Tanfanercept Ophthalmic Solution, Placebo
- Drug
- Lead sponsor
- HanAll BioPharma Co., Ltd.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 260 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2022
- U.S. locations
- 10
- States / cities
- Phoenix, Arizona • Glendale, California • Newport Beach, California + 7 more
- Conditions
- Diarrhea Travelers, Antibiotic Resistant Infection
- Interventions
- Bismuth subsalicylate, Placebo
- Drug
- Lead sponsor
- Centers for Disease Control and Prevention
- Federal
- Eligibility
- 18 Years to 69 Years
- Enrollment
- 482 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2018 – 2026
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Clostridium Difficile
- Interventions
- Misoprostol 100Mcg Tab, Placebo
- Drug · Other
- Lead sponsor
- Vanderbilt University Medical Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 6 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2021
- U.S. locations
- 3
- States / cities
- St Louis, Missouri • Chapel Hill, North Carolina • Nashville, Tennessee
- Conditions
- Huntington's Disease
- Interventions
- Memantine
- Drug
- Lead sponsor
- Jody Corey-Bloom, MD, PhD
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2009
- U.S. locations
- 3
- States / cities
- La Jolla, California • Kansas City, Kansas • Baltimore, Maryland
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- HE3286, Placebo
- Drug
- Lead sponsor
- Harbor Therapeutics
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 164 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2010
- U.S. locations
- 22
- States / cities
- Anaheim, California • Beverly Hills, California • Buena Park, California + 17 more
- Conditions
- Schizophrenia
- Interventions
- Placebo, 3-(2,4 dimethoxybenzylidene anabaseine) 150 mg, 3-(2,4 dimethoxybenzylidene anabaseine) 75 mg
- Drug
- Lead sponsor
- University of Colorado, Denver
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 29 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2007
- U.S. locations
- 1
- States / cities
- Denver, Colorado
- Conditions
- Atrial Fibrillation
- Interventions
- Ranolazine, Dronedarone, Ranolazine placebo, Dronedarone placebo
- Drug
- Lead sponsor
- Gilead Sciences
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 134 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2014
- U.S. locations
- 15
- States / cities
- Beverly Hills, California • Newport Beach, California • San Francisco, California + 12 more
- Conditions
- Autism Spectrum Disorder (ASD)
- Interventions
- BUMETANIDE (S95008) for week 0 - 26, PLACEBO for week 0 - 26, Open-Label BUMETANIDE (S95008) for weeks 26 - 52
- Drug
- Lead sponsor
- Institut de Recherches Internationales Servier
- Other
- Eligibility
- 2 Years to 6 Years
- Enrollment
- 211 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2021
- U.S. locations
- 1
- States / cities
- Staten Island, New York
- Conditions
- Schizophrenia
- Interventions
- D-cycloserine, Glycine, Clozapine, Placebo
- Drug
- Lead sponsor
- Massachusetts General Hospital
- Other
- Eligibility
- 18 Years to 65 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1998 – 2005
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Asthma
- Interventions
- BD MDI 320 µg, BD MDI 160 µg, BD MDI 80 µg, BD MDI 40 µg, Placebo MDI
- Drug
- Lead sponsor
- Pearl Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 147 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2015
- U.S. locations
- 41
- States / cities
- Athens, Alabama • Birmingham, Alabama • Foley, Alabama + 37 more
- Conditions
- Congestive Heart Failure
- Interventions
- SLV320
- Drug
- Lead sponsor
- Solvay Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 300 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2007 – 2008
- U.S. locations
- 10
- States / cities
- Whittier, California • Largo, Florida • Miami, Florida + 7 more
- Conditions
- Hyperphagia, Prader-Willi Syndrome
- Interventions
- Placebo, ARD-101
- Drug
- Lead sponsor
- Aardvark Therapeutics, Inc.
- Industry
- Eligibility
- 7 Years and older
- Enrollment
- 68 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2026
- U.S. locations
- 17
- States / cities
- Birmingham, Alabama • Encinitas, California • Orange, California + 14 more